Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive

Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive

Objective Natalizumab is a new and efficient treatment for multiple sclerosis (MS). The risk of developing progressive multifocal leukoencephalopathy (PML) during the use of this drug has created the need for better comprehension of JC virus (JCV) infection. The objective of the present study was to...

Full description

Bibliographic Details
Main Authors: Yara Dadalti Fragoso, Maria Fernanda Mendes, Walter Oleschko Arruda, Jefferson Becker, Joseph Bruno Bidin Brooks, Margarete de Jesus Carvalho, Elizabeth Regina Comini-Frota, Renan Barros Domingues, Maria Lucia Brito Ferreira, Alessandro Finkelsztejn, Paulo Diniz da Gama, Sidney Gomes, Marcus Vinicius Magno Goncalves, Damacio Ramon Kaimen-Maciel, Rogerio de Rizo Morales, Andre Muniz, Heloisa Helena Ruocco, Pedro Rippel Salgado, Livia Brito Bezerra de Albuquerque, Rodrigo Assad Diniz da Gama, Sergio Georgeto, Josiane Lopes, Celso Luis Silva Oliveira, Francisco Tomaz Meneses Oliveira, Juliana Safanelli, Patricia Correia de Oliveira Saldanha, Massaco Satomi
Format: Article
Language:English
Published: Academia Brasileira de Neurologia (ABNEURO) 2013-10-01
Series:Arquivos de Neuro-Psiquiatria
Subjects:
esclerose multipla
natalizumabe
JC virus
leucoencefalopatia multifocal progressiva
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2013001100780&lng=en&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2013001100780&lng=en&tlng=en

Similar Items